IDH2 and plasma cell myeloma: Previous studies have demonstrated that in multiple myeloma, IDH2 enhances the expression of WNT7B and activates the WNT signaling pathway by targeting the m6A demethylase FTO, thereby promoting the occurrence and development of multiple myeloma [31].